Figure 2. Updated follow-up data for 18 patients with NSCLC presented at the Company's first R&D Day on Oct. 31, 2025 (Cohort 1A: immunotherapy-pretreated non-squamous NSCLC; Cohort 2A: first-line non-squamous NSCLC; Cohort 2B: first-line squamous NS

Figure 2. Updated follow-up data for 18 patients with NSCLC presented at the Company's first R&D Day on Oct. 31, 2025 (Cohort 1A: immunotherapy-pretre

Figure 2. Updated follow-up data for 18 patients with NSCLC presented at the Company's first R&D Day on Oct. 31, 2025 (Cohort 1A: immunotherapy-pretreated non-squamous NSCLC; Cohort 2A: first-line non-squamous NSCLC; Cohort 2B: first-line squamous NSCLC).

Format

PNG

Quelle:

LEADS BIOLABS CO., LTD.

Downloads